Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer
Authors
Keywords
EED, SUZ12, EZH2, Colorectal cancer
Journal
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume 141, Issue 4, Pages 661-669
Publisher
Springer Nature
Online
2014-10-18
DOI
10.1007/s00432-014-1854-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Association between EZH2 polymorphisms and colorectal cancer risk in Han Chinese population
- (2014) Jian Wang et al. MEDICAL ONCOLOGY
- SUZ12 is involved in progression of non-small cell lung cancer by promoting cell proliferation and metastasis
- (2014) Chunhua Liu et al. TUMOR BIOLOGY
- EZH2: biology, disease and structure-based drug discovery
- (2013) Jin-zhi Tan et al. ACTA PHARMACOLOGICA SINICA
- SUZ12 Depletion Suppresses the Proliferation of Gastric Cancer Cells
- (2013) Yingjun Cui et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Epigenetic regulation of colon cancer and intestinal stem cells
- (2013) Saher Sue Hammoud et al. CURRENT OPINION IN CELL BIOLOGY
- Inhibition of Enhancer of Zeste Homolog 2 (EZH2) Expression Is Associated With Decreased Tumor Cell Proliferation, Migration, and Invasion in Endometrial Cancer Cell Lines
- (2013) Ramez N. Eskander et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Targeted disruption of the EZH2–EED complex inhibits EZH2-dependent cancer
- (2013) Woojin Kim et al. Nature Chemical Biology
- EZH2 Promotes Malignant Behaviors via Cell Cycle Dysregulation and Its mRNA Level Associates with Prognosis of Patient with Non-Small Cell Lung Cancer
- (2013) Wei Cao et al. PLoS One
- Update of research on the role of EZH2 in cancer progression
- (2013) Liang Shen et al. OncoTargets and Therapy
- Bmi-1 Promotes the Chemoresistance, Invasion and Tumorigenesis of Pancreatic Cancer Cells
- (2012) Tao Yin et al. CHEMOTHERAPY
- EZH2 Methyltransferase and H3K27 Methylation in Breast Cancer
- (2012) Kyung Hyun Yoo et al. International Journal of Biological Sciences
- SUZ12 Promotes Human Epithelial Ovarian Cancer by Suppressing Apoptosis via Silencing HRK
- (2012) H. Li et al. MOLECULAR CANCER RESEARCH
- PRC2/EED-EZH2 Complex Is Up-Regulated in Breast Cancer Lymph Node Metastasis Compared to Primary Tumor and Correlates with Tumor Proliferation In Situ
- (2012) Hongxiang Yu et al. PLoS One
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome
- (2011) Yun Gong et al. CANCER
- Gene Silencing by the Polycomb Group Proteins and Associations With Cancer
- (2011) Yan-Wei Lin et al. CANCER INVESTIGATION
- EZH2 Promotes Malignant Phenotypes and Is a Predictor of Oral Cancer Development in Patients with Oral Leukoplakia
- (2011) W. Cao et al. Cancer Prevention Research
- Studies on the Expression Patterns of Class I PI3K Catalytic Subunits and Its Prognostic Significance in Colorectal Cancer
- (2011) Binbin Cui et al. CELL BIOCHEMISTRY AND BIOPHYSICS
- EZH2 Depletion Blocks the Proliferation of Colon Cancer Cells
- (2011) Bettina Fussbroich et al. PLoS One
- Cancer epigenetics: above and beyond
- (2011) Mariana Brait et al. TOXICOLOGY MECHANISMS AND METHODS
- Roles of the Polycomb group proteins in stem cells and cancer
- (2011) H Richly et al. Cell Death & Disease
- Deregulated Expression of the Polycomb-Group Protein SUZ12 Target Genes Characterizes Mantle Cell Lymphoma
- (2010) Daniel Martín-Pérez et al. AMERICAN JOURNAL OF PATHOLOGY
- Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo
- (2010) Sha Hu et al. CANCER BIOLOGY & THERAPY
- The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer
- (2010) Liudmila L. Kodach et al. CARCINOGENESIS
- Epigenetic factors in cancer development: Polycomb group proteins
- (2010) Andrea Piunti et al. Future Oncology
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- (2010) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Loss of miR-200 Inhibition of Suz12 Leads to Polycomb-Mediated Repression Required for the Formation and Maintenance of Cancer Stem Cells
- (2010) Dimitrios Iliopoulos et al. MOLECULAR CELL
- EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis
- (2010) Cheng-Gang Wang WORLD JOURNAL OF GASTROENTEROLOGY
- The value of EZH2, p27kip1, BMI-1 and MIB-1 on biopsy specimens with low-risk prostate cancer in selecting men with significant prostate cancer at prostatectomy
- (2009) Tineke Wolters et al. BJU INTERNATIONAL
- Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis
- (2009) Ø Fluge et al. BRITISH JOURNAL OF CANCER
- Epigenetics in cancer
- (2009) S. Sharma et al. CARCINOGENESIS
- Expression level of Bmi-1 oncoprotein is associated with progression and prognosis in colon cancer
- (2009) Da-wei Li et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Epigenetic contributions to cancer metastasis
- (2008) David I. Rodenhiser CLINICAL & EXPERIMENTAL METASTASIS
- Roles of the EZH2 histone methyltransferase in cancer epigenetics
- (2008) Jeffrey A. Simon et al. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
- The Bmi-1 polycomb group gene in skin cancer: regulation of function by (−)-epigallocatechin-3-gallate
- (2008) Sivaprakasam Balasubramanian et al. NUTRITION REVIEWS
- Genomewide Analysis of PRC1 and PRC2 Occupancy Identifies Two Classes of Bivalent Domains
- (2008) Manching Ku et al. PLoS Genetics
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started